Effect of solvent and hydrogen during selective hydrogenation
摘要:
Described is the solvent effect for the chemoselective hydrogenation of alkenes having a benzyloxy group (Bn-O-) using a hydrogenation system employing atomic hydrogen permeating through a Pd sheet electrode. (C) 2001 Elsevier Science Ltd. All rights reserved.
different alkene affords unsymmetrical, multi-substituted pyridine derivatives. Mechanistic studies indicate that the reaction proceeds via electrophilic thallation of heteroarenes followed by Pd-catalyzed Heck-type reaction. The utility of this method is showcased by its application to the late-stage functionalization of structurally complex bioactive molecules having 2,6-dialkoxypyridine as a core
Chemoselective hydrogenation of olefinic double bonds without concomitant hydrogenolysis of allylic and benzylic C-O linkages was performed successfully by the aid of active hydrogen permeated through a Pd sheet electrode.
Pd black deposited on polypropylene sheet as a highly selective catalyst for hydrogenation of alkenes
A catalyst deposited on a polypropylene sheet having an activity of almost the same level as commercially available Pd black and capable of promoting hydrogenolysis-free hydrogenation was developed. (C) 2003 Elsevier Science Ltd. All rights reserved.
Novel Hypotensive Agents from <i>Verbesina </i><i>ca</i><i>racasana</i>. 6. Synthesis and Pharmacology of Caracasandiamide
作者:Marco Carmignani、Anna R. Volpe、Franco Delle Monache、Bruno Botta、Romulo Espinal、Stella C. De Bonnevaux、Carlo De Luca、Maurizio Botta、Federico Corelli、Andrea Tafi、Giuseppe Ripanti、Giuliano Delle Monache
DOI:10.1021/jm991004l
日期:1999.8.1
Caracasancliamide, a second hypotensive agent isolated from Verbesina caracasana, is the cyclobutane dimer (truxinic type) of the previously reported 1-[(3,4-dimethoxycinnamoyl)amino]-4-[(3-methyl-2-butenyl)guanidino]butane (caracasanamide) (Delle Monache, G.; et al. BioMed. Chem. Lett. 1992, 25, 415-418). The structure was confirmed by synthesis starting from beta-truxinic acid obtained by photoaddition of 3,4-dimethoxycinnamic acid. The dimer was coupled with 2 mol of prenylagmatine to give caracasandiamide in satisfactory yield. By contrast, the direct photodimerization of caracasanamide was unsuccessful. Caracasandiamide, assayed by the iv route in anesthetized rats at doses ranging from 50 to 3200 mu g/kg of body weight, was found to have! no appreciable effect on heart rate. At lower doses, the drug stimulates breathing and increases cardiac inotropism, stroke volume, and cardiac output, thus augmenting blood pressure and aortic flow. At higher doses, caracasandiamide depresses breathing likely through central neurogenic mechanisms (not involved in the cardiovascular effects), continues to stimulate cardiac inotropism, and induces, by reducing peripheral vascular resistance, arterial hypotension with reduction of both aortic flow and stroke volume. These cardiovascular effects appear to involve complex interactions at the level of the peripheral beta(1)-, beta(2)-, and alpha(2)-adrenoreceptor-dependent as well as M-2- and M-4-cholinergic receptor-dependent transductional pathways both in cardiovascular myocells and at the level of the postganglionic sympathetic endings (with reserpine- and guanethidine-like mechanisms). The cardiovascular effects of caracasandiamide, different from those of caracasanamide, do not depend, on significant actions on the central nervous system and on baroreflex path-ways. In a similar manner and more effective than caracasanamide, caracasandiamide may be considered a hypotensive and antihypertensive drug. It is devoid of some of the negative side effects, e.g., reflex tachycardia and decreased cardiac inotropism, which are shown by the majority of the most common antihypertensive and vasodilator drugs.